JPMorgan lowered the firm’s price target on Novavax (NVAX) to $6 from $7 and keeps an Underweight rating on the shares. The firm sees limited commercial upside for the company with no material pipeline catalysts next year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax price target lowered to $16 from $18 at B. Riley
- Novavax call volume above normal and directionally bullish
- Novavax’s Strong Financial Outlook and Strategic Partnerships Support Buy Rating
- Novavax Reports Q3 2025 Earnings and Strategic Progress
- Novavax’s Q3 2025 Earnings Call: Optimistic Outlook